



Date: 13-02-2023

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting and intimation under Regulation 30 (read with Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, the Board of Directors of the Company in their Meeting held today i.e., Monday, February 13th 2023, inter alia have considered and approved following important businesses:

I. Approval of the Un-audited Financial Results for Quarter ended December 31st, 2022

In continuation to our intimation dated February 3rd, 2023 regarding the Notice for the Board Meeting, we would like to inform you that the Board of Directors (“Board”) of Pharmaids Pharmaceuticals Limited (the “Company”) at its Meeting has inter-alia, considered and approved the Unaudited Financial Results along with the Limited Review Report for the Quarter ended December 31st, 2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) which has been duly reviewed and recommended by the Audit Committee.

We are enclosing herewith the Unaudited Financial Results along with the Limited Review Report signed by M/s PPKG & Co, Statutory Auditors of the Company.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com.

II. To Consider and Approve taking 5791sq.mtrs. (Approx. 1.43 Acres) of land on Sub-lease and authorisation for entering into Sub-lease agreement.

The Board approved to take 5791sq.mtrs. (approx.1.43 acres) of land on Sub-lease from Vaishnavi Enterprises (Sub-lessor) located at Avverahalli (Dobbaspeth 4th Phase) Industrial Area, for setting up Preclinical and Chemistry Research & Development Facility.



Pharmaids Pharmaceuticals Limited

The Board Further approved draft Sub-lease agreement to be executed by and between the Company and Vaishnavi Enterprises (Sub-lessor), subject to further modifications, if needed be, as may be mutually agreeable.

The Board Meeting commenced at 12:00 Noon and the agenda items for approval of the above-mentioned items were concluded at 2:45 PM.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar
(Company Secretary & Head-Legal)



Pharmaids Pharmaceuticals Limited

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS PERIOD ENDED 31ST DECEMBER 2022:

Rs. (In Lakhs)

S No.	Particulars	Quarter Ended			Nine Months Period Ended		Year ended
		Unaudited (Reviewed)			Unaudited (Reviewed)		Audited
		Dec 31, 2022	Sep 30, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021	Mar 31, 2022
1	Revenue	-	-	72.39	-	363.67	393.93
2	Other Income	-	-	-	-	-	1.51
3	Total Income	-	-	72.39	-	363.67	395.44
4	Expenses	-	-	-	-	-	-
	a) Cost of Material Consumed	-	-	-	-	-	0.00
	b) Purchase of Stock in Trade	-	-	72.07	-	379.34	409.00
	c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	(6.01)	-	(47.58)	(51.85)
	d) Employee Benefit Expenses	37.19	31.55	2.27	70.83	5.81	4.44
	e) Finance Cost	-	0.02	-	0.28	-	0.27
	f) Depreciation and Amortisation Expenses	0.83	0.63	0.08	1.55	0.84	0.92
	g) Other Expenses	32.26	21.98	2.41	57.62	12.12	18.63
	Total Expenses	70.28	54.18	70.82	130.28	350.53	381.41
5	Profit/(loss) before Exceptional items and Tax	(70.28)	(54.18)	1.57	(130.28)	13.14	14.03
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before tax	(70.28)	(54.18)	1.57	(130.28)	13.14	14.03
8	Tax expense:						
	(1) Current tax	-	-	-	-	-	0.00
	(2) Deferred tax	0.31	0.36	0.15	9.15	3.43	(0.49)
9	Profit (Loss) for the period from continuing operations	(70.59)	(54.54)	1.42	(139.43)	9.71	14.52
10	Profit/(loss) from discontinued operations	-	-	-	-	-	-
11	Tax expense of discontinued operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
13	Profit/(loss) for the period	(70.59)	(54.54)	1.42	(139.43)	9.71	14.52

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520TG1989PLC009679)

Registered Office: 4-4-211/212/3, Inderbagh, Sulthan Bazar, Hyderabad 500095 INDIA

Phone: 040-40122151 Email: pharmaids@pharmaids.com / pharmaids125@gmail.com WEB: www.pharmaids.com

Executive Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA



Pharmaids Pharmaceuticals Limited

14	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15	Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-	-
16	Earnings per equity share (for continuing operation):						
	(1) Basic	(0.54)	(0.53)	0.01	(1.07)	0.09	0.14
	(2) Diluted	(0.50)	(0.53)	0.01	(1.00)	0.09	0.14

NOTES:

1. The above results were reviewed and recommended by the Audit committee and approved by the Board of Directors at its meeting held on February 13th, 2023.
2. These financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act, 2013, read together with the Companies (Indian Accounting Standards - Ind AS) Rules issued thereafter and the provisions of the Companies Act 2013, as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI") and other recognised accounting principles and policies generally accepted in India to the extent possible. These financial results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with other relevant rules and circulars issued thereunder.
3. The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended and nine months ended on 31st December 2022 in pursuance to regulation 33(c)(i) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with other relevant rules and circulars issued thereunder. The statutory auditors have expressed an unmodified review report.



Pharmaids Pharmaceuticals Limited

4. The Company operates in a single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
5. Previous period figures have been reclassified and regrouped wherever considered necessary to conform to the current period figures.

Date: 13-02-2023

Place: Bangalore

For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON
REVIEW OF INTERIM FINANCIAL RESULTS**

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited.

We have reviewed the accompanying statement of unaudited Financial Results of PHARMAIDS PHARMACEUTICALS LIMITED ("the Company") for the quarter and nine months ended 31st December, 2022 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular no CIRJCFD/CMD1/44/2019 dated march 29,2019("the Circular").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 , as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co.
Chartered Accountants
FRN No. 009655S

GirdhariLal Toshniwal

GirdhariLal Toshniwal
(Partner)
M. No.: 205140
UDIN:



Place: Hyderabad
Date: 13-02-2023

UDIN : 23205140BGUNGR4465